查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1247466

2023-2030 年全球原位雜交 (ISH) 市場

Global In Situ Hybridization Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

原位雜交的全球市場預計到 2022 年將達到 97.4 億美元，到 2030 年將達到 150.8746 億美元。 在預測期內（2023 年至 2030 年），該市場的複合年增長率為 11.9%。

原位雜交 (ISH) 使用標記的互補 DNA、RNA 或修飾的核酸鏈（即探針）來識別組織或組織的一部分或部分中的特定 DNA 或 RNA 序列。當足夠小時，它定位於整個組織（例如，植物種子、果蠅胚胎）、細胞和循環腫瘤細胞 (CTC) 內。 通常將蛋白質定位到組織切片的免疫組織化學是不同的。

市場動態

癌症患者人數上升

吸煙和不良的飲食習慣會增加癌症的發病率。 這是 ISH 市場的主要增長因素。 例如，世界衛生組織報告說，癌症將成為 2020 年全球死亡的主要原因，約有 1000 萬人死亡，即每 6 人中就有 1 人死亡。 乳腺癌、肺癌、結腸癌、直腸癌和前列腺癌是最常見的癌症類型。 煙草使用、高度肥胖、飲酒、飲食中水果和蔬菜含量低以及缺乏鍛煉約佔癌症死亡人數的三分之一。

在低收入和中等收入國家，人乳頭瘤病毒 (HPV) 和肝炎等致癌感染被認為佔癌症病例的 30%。 因此，原位雜交的需求在預計期間將會增加。

缺乏訓練有素的人力阻礙了市場。

為了執行基於 ISH 的測試，必須熟悉染色體和基因的分子規格。 從手動轉向自動化的阻力也阻礙了行業的發展。 對於許多供應商來說，從手動和過時的流程遷移到基於 IT 的流程即使不是不可能，也是很困難的。 出於這個原因，基於 ISH 的診斷的廣泛使用受到合格、受過教育和技術熟練的實驗室人員短缺的限制，特別是在發展中國家。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 片段類型
  • 按應用程序摘錄
  • 最終用戶的片段
  • 區域摘要

第 4 章動力學

  • 影響因子
    • 司機
      • 癌症發病率增加
      • 了解伴隨診斷
    • 約束因素
      • 缺乏訓練有素的人力阻礙了市場
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 未滿足的需求
  • 管道解析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章副產品

  • 消耗品
  • 儀器
  • 軟件

第八章技術

  • 魚
    • DNA魚
    • RNA 魚
    • 巴拿馬魚
  • 師叔

第 9 章按應用

  • 癌症診斷劑
  • 細胞學
  • 傳染病診斷試劑
  • 神經科學
  • 免疫學

第 10 章最終用戶

  • 醫院/診斷藥物研究所
  • 學術和研究機構等
  • 製藥和生物技術公司
  • 委託研究機構

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 俄羅斯
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第13章公司簡介

  • 雅培實驗室
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • F. Hoffmann-La Roche Ag.
  • Becton, Dickinson And Company
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Creative Bioarray
  • Biocat Gmbh
  • Zytovision.

第14章 附錄

簡介目錄
Product Code: BT3183

Market Overview

The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).

In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.

Market Dynamics

The Increasing incidence of Cancer cases

Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.

In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.

The Lack of trained personnel will hamper the market.

To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.

Segment Analysis

The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.

On basis of the technology, FISH isexpected to hold the largest share

The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.

For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.

Geographical Penetration

Rising higher rates of infectious diseases, genetic abnormalities drives the region

North America'sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.

Competitive Landscape

The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.

COVID-19 Impact Analysis

By Product

  • Consumables
  • Instruments
  • Software

By Technology

  • FISH
    • DNA FISH
    • RNA FISH
    • PNA FISH
  • CISH

By Application

  • Cancer Diagnostics
  • Cytology
  • Infectious Disease Diagnostics
  • Neuroscience
  • Immunology

By End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract research organizations

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In April 6, 2021, A strategic business relationship between Applied Spectral Imaging (ASI) and KromaTiD, Inc. has been announced. Under this partnership, ASI will have the exclusive worldwide rights to offer Pinpoint FISH (PPF) probes and test services developed by KromaTiD.
  • In March 10, 2020, an Improved FISH Probe is Introduced by Creative Bioarray to Identify 2019 New Coronavirus. Viral particles in infected cells can be recognized using in site hybridization (ISH), which also offers precise molecular identification and visualization of infected cell types and regions.
  • On May 26, 2020, The CE-IVD designated RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform has been made available in Europe by Leica Biosystems and Bio-Techne. Leica's platform and Bio-RNAscope Techne will give pathologists access to the top applications to help their diagnostics labs.

Why Purchase the Report?

  • To visualize the global In Situ Hybridization- market segmentation based on product, technology, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of In Situ Hybridization market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of Cancer cases
      • 4.1.1.2. Awareness about companion diagnostics
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of trained personnel will hamper the market
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet needs
  • 5.6. Pipe line analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Instruments
  • 7.4. Software

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. FISH*
    • 8.2.1. DNA FISH
    • 8.2.2. RNA FISH
    • 8.2.3. PNA FISH
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. CISH

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Cancer Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cytology
  • 9.4. Infectious Disease Diagnostics
  • 9.5. Neuroscience
  • 9.6. Immunology

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Hospitals & Diagnostic Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Academic & Research Institutes
  • 10.4. Pharmaceutical & Biotechnology Companies
  • 10.5. Contract research organizations

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Russia
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ag.
  • 13.3. Becton, Dickinson And Company
  • 13.4. Agilent Technologies, Inc.
  • 13.5. Thermo Fisher Scientific
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. Bio-Techne Corporation
  • 13.8. Creative Bioarray
  • 13.9. Biocat Gmbh
  • 13.10. Zytovision.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us